Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics says Sanofi ends SAR448272 program, removing its milestones

Negative Impact 3 of 5 product/contract Written later

Nurix Therapeutics said on November 3, 2026 that collaboration partner Sanofi has discontinued the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminated the program. As a result, Nurix does not expect to receive the development, regulatory and commercial milestone payments or royalties it was eligible for on that program, though it remains eligible for payments on other licensed programs under the Sanofi collaboration.

Key points

  • Sanofi notified Nurix on November 3, 2026 that it is discontinuing the Phase 1 first-in-human trial of SAR448272 and terminating the program
  • Nurix does not expect any future development, regulatory or commercial milestone payments or royalties tied to SAR448272
  • Nurix remains eligible for milestones and royalties on other licensed programs, which Sanofi may further develop at its discretion

The filing

CompanyNurix Therapeutics, Inc. (NRIX)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:02 PM ET
Accession number0001549595-26-000055

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.